S
Sumanta K. Pal
Researcher at City of Hope National Medical Center
Publications - 718
Citations - 14893
Sumanta K. Pal is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 56, co-authored 614 publications receiving 10390 citations.
Papers
More filters
Journal ArticleDOI
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
Toni K. Choueiri,Robert J. Motzer,Brian I. Rini,J.B.A.G. Haanen,Matthew T. Campbell,Balaji Venugopal,Christian K. Kollmannsberger,G. Gravis-Mescam,Motohide Uemura,J.-L. Lee,Marc-Oliver Grimm,Howard Gurney,Manuela Schmidinger,James Larkin,Michael B. Atkins,Sumanta K. Pal,Jing Wang,Mariangela Mariani,S. Krishnaswami,P. Cislo,Aleksander Chudnovsky,Camilla Fowst,Bo Huang,A. di Pietro,Laurence Albiges +24 more
TL;DR: Among patients with previously untreated aRCC, treatment with avelumab plus axit inib continued to result in a statistically significant improvement in PFS vs sunitinib; OS data were still immature.
Journal ArticleDOI
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study
Jenny J. Ko,Wanling Xie,Nils Kroeger,Jae-Lyun Lee,Brian I. Rini,Jennifer J. Knox,Georg A. Bjarnason,Sandy Srinivas,Sumanta K. Pal,Takeshi Yuasa,Martin Smoragiewicz,Frede Donskov,Ravindran Kanesvaran,Lori Wood,D. Scott Ernst,Neeraj Agarwal,Ulka N. Vaishampayan,Sun Young Rha,Toni K. Choueiri,Daniel Y.C. Heng +19 more
TL;DR: The IMDC prognostic model in the second-line targeted therapy setting has an improved prognostic performance and is applicable to a more contemporary patient cohort than that of the three-factor MSKCC model.
Journal ArticleDOI
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Robert J. Motzer,Paul B. Robbins,Thomas Powles,Laurence Albiges,John B. A. G. Haanen,James Larkin,Xinmeng Jasmine Mu,Keith A. Ching,Motohide Uemura,Sumanta K. Pal,Boris Alekseev,Gwenaelle Gravis,Matthew T. Campbell,Konstantin Penkov,Jae-Lyun Lee,Subramanian Hariharan,Xiao Wang,Weidong Zhang,Jing Wang,Aleksander Chudnovsky,Aleksander Chudnovsky,Alessandra di Pietro,Amber C Donahue,Toni K. Choueiri +23 more
TL;DR: Important biological features associated with differential PFS between the treatment arms are identified, including new immunomodulatory and angiogenesis gene expression signatures (GESs), previously undescribed mutational profiles and their corresponding GESs, and several HLA types.
Journal ArticleDOI
Bladder cancer, version 5.2017: Clinical practice guidelines in oncology
Philippe E. Spiess,Neeraj Agarwal,Rick Bangs,Stephen A. Boorjian,Mark K. Buyyounouski,Peter E. Clark,Tracy M. Downs,Jason A. Efstathiou,Thomas W. Flaig,Terence W. Friedlander,Richard E. Greenberg,Khurshid A. Guru,Noah M. Hahn,Harry W. Herr,Christopher J. Hoimes,Brant A. Inman,Masahito Jimbo,A. Karim Kader,Subodh M. Lele,Joshua J. Meeks,Jeff M. Michalski,Jeffrey S. Montgomery,Lance C. Pagliaro,Sumanta K. Pal,Anthony L. Patterson,Elizabeth R. Plimack,Kamal S. Pohar,Michael P. Porter,Mark A. Preston,Wade J. Sexton,Arlene O. Siefker-Radtke,Guru Sonpavde,Jonathan D. Tward,Geoffrey Wile,Mary A. Dwyer,Lisa A. Gurski +35 more
TL;DR: The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.
Journal ArticleDOI
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.
Sumanta K. Pal,Jonathan E. Rosenberg,Jean H. Hoffman-Censits,Raanan Berger,David I. Quinn,Matthew D. Galsky,Juergen Wolf,Christian Dittrich,Bhumsuk Keam,Jean Pierre Delord,Jan H.M. Schellens,Gwenaelle Gravis,J. Medioni,Pablo Maroto,Virote Sriuranpong,Chaiyut Charoentum,Howard A. Burris,Viktor Grünwald,Daniel P. Petrylak,Ulka N. Vaishampayan,Eliahu Gez,Ugo De Giorgi,Jae-Lyun Lee,Jens Voortman,Sumati Gupta,Sunil Sharma,Amir Mortazavi,David J. Vaughn,Randi Isaacs,Katie Parker,Xueying Chen,Kun Yu,Dale Porter,Diana Graus Porta,Dean F. Bajorin +34 more
TL;DR: BJJ398 is active in patients with alterations in FGFR3, resulting in both reductions in tumor volume and stabilization of disease, highlighting putative mechanisms of resistance to the agent, which may be useful in following disease status.